These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

757 related items for PubMed ID: 23079063

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
    Kuykendall JR.
    Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP.
    Cancer; 2007 Jan 15; 109(2):265-73. PubMed ID: 17133405
    [Abstract] [Full Text] [Related]

  • 10. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M, Jiang Q, Xie Y.
    Clin Lymphoma Myeloma Leuk; 2015 Jan 15; 15(1):22-8. PubMed ID: 25042977
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G, Teofili L, Voso MT, Lübbert M.
    Haematologica; 2002 Dec 15; 87(12):1324-41. PubMed ID: 12495905
    [Abstract] [Full Text] [Related]

  • 13. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
    Wijermans PW, Lübbert M, Verhoef G, Klimek V, Bosly A.
    Ann Hematol; 2005 Dec 15; 84 Suppl 1():9-17. PubMed ID: 16211386
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C, Hackanson B, Stresemann C, Lübbert M, Lyko F.
    Cancer Res; 2005 Aug 15; 65(16):7086-90. PubMed ID: 16103056
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
    Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF.
    J Clin Oncol; 2010 Feb 01; 28(4):556-61. PubMed ID: 20026803
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.